Vir Biotechnology (VIR) Deferred Taxes (2018 - 2024)
Vir Biotechnology (VIR) posted Deferred Taxes of -$2.6 million for Q4 2024, down 4736.84% sequentially from $57000.0 in Q3 2024, and down 148.64% YoY from $5.4 million in Q1 2024.
Powered by 
Analysis
Vir Biotechnology (VIR) Deferred Taxes (2018 - 2024) Analysis & Trends
Vir Biotechnology has reported Deferred Taxes for 3 years, with the latest figure at -$2.6 million in Q4 2024.
- Quarterly Deferred Taxes fell 148.64% year-over-year to -$2.6 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$3.6 million (changed N/A YoY) and the FY2024 annual result came in at -$2.9 million, down 177.42% from the prior year.
- Deferred Taxes eased to -$2.6 million in Q4 2024 per VIR's latest filing, from $57000.0 in the prior quarter.
- Over five years, Deferred Taxes peaked at $57000.0 in Q3 2024 and troughed at -$2.6 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.66 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Vir Biotechnology | 1.92 Bn | 1.92 Bn | 238.95 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -2.64 Mn |
| Sep 30, 2024 | 57,000.00 |
| Dec 31, 2023 | -1.06 Mn |
| Dec 31, 2018 | 980,000.00 |